Health · Medical Research · 6 hrs ago
Oxaloacetate Linked to Improved Cognitive Symptoms in Breast Cancer Survivors
A preliminary study found improved cancer-related cognitive impairment after treatment with oxaloacetate, a glutamate regulator.
The study involved breast cancer survivors experiencing cognitive problems linked to cancer.
Sixteen patients were evaluable for the study’s results.
The findings suggest oxaloacetate may help with these symptoms.
But the study was single-arm, so it did not include a comparison group.
The results are preliminary and do not establish how well the treatment works more broadly.
A preliminary single-arm clinical study found that cancer-related cognitive impairment improved significantly in breast cancer survivors treated with oxaloacetate.
Oxaloacetate is described as a glutamate regulator.
The report said 16 patients were evaluable.
The source article was published by MedPage Today on October 23, 2026.
- Who
- Breast cancer survivors with cancer-related cognitive impairment. The study had 16 evaluable patients.
- What
- A preliminary single-arm clinical study found significant improvement after treatment with oxaloacetate.
- When
- The MedPage Today article was published on October 23, 2026; the study treatment dates are not stated.
- Where
- Not stated.
- Why
- Not stated.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Study design
- Preliminary, single-arm clinical study
- Treatment
- Oxaloacetate, described as a glutamate regulator
- Evaluable patients
- 16
- Reported outcome
- Significant improvement in cancer-related cognitive impairment
- Article publication
- October 23, 2026 |